Page last updated: 2024-11-13
perfluorobutylpentane
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
perfluorobutylpentane: used for removing silicone oil from the surface of silicone intraocular lenses [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 22002932 |
SCHEMBL ID | 1768870 |
MeSH ID | M0527166 |
Synonyms (13)
Synonym |
---|
SCHEMBL1768870 |
1,1,1,2,2,3,3,4,4-nonafluorononane 97% |
perfluorobutylpentane |
1190430-21-7 |
mfcd22123953 |
1-(perfluorobutyl)pentane |
1,1,1,2,2,3,3,4,4-nonafluorononane |
CS-0210932 |
DTXSID70895167 |
gydmbtytwynrgo-uhfffaoysa-n |
BS-26090 |
nonane, 1,1,1,2,2,3,3,4,4-nonafluoro- |
M4M23ZL2AD |
Research Excerpts
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
"Siluron2000 silicone oil seems to be equally safe and effective as Siluron5000 oil but allows for better handling with the potential of reducing procedure time." | ( COHORT SAFETY AND EFFICACY STUDY OF SILURON2000 EMULSIFICATION-RESISTANT SILICONE OIL AND F4H5 IN THE TREATMENT OF FULL-THICKNESS MACULAR HOLE. Pinxten, AM; Stalmans, P; Wong, DS, 2015) | 0.42 |
Bioavailability
Excerpt | Reference | Relevance |
---|---|---|
" This was evaluated in anesthetised and conscious rats and mini-pigs, to measure the relative bioavailability of propofol following buccal administration, but also partly to evaluate the animal models used for this investigation." | ( Buccal absorption of propofol when dosed in 1-perfluorobutylpentane to anaesthetised and conscious Wistar rats and Göttingen mini-pigs. Holm, P; Holm, R; Quintel, M; Theisinger, S; Thiel, M; Tsagogiorgas, C, 2013) | 0.65 |
" Corneal bioavailability of cyclosporine A (CsA) dissolved in perfluorobutylpentane (F4H5) or perfluorohexyloctane (F6H8) was compared to commercially available CsA ophthalmic emulsions, Restasis® and Ikervis®." | ( Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs. Agarwal, P; Günther, B; Rupenthal, ID; Scherer, D, 2018) | 0.72 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (12)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (8.33) | 29.6817 |
2010's | 11 (91.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 28.07
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (28.07) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (8.33%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 11 (91.67%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |